Qiagen (NYSE:QGEN) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Qiagen (NYSE:QGEN) issued its quarterly earnings results on Wednesday. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01, Zacks reports. The firm had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a return on equity of 14.82% and a net margin of 20.33%.The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 earnings per share. Qiagen updated its FY 2026 guidance to 2.500- EPS and its Q1 2026 guidance to 0.540- EPS.

Qiagen Price Performance

Shares of QGEN opened at $51.17 on Friday. The company’s 50-day moving average is $49.63 and its 200-day moving average is $49.67. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. The firm has a market capitalization of $10.81 billion, a PE ratio of 25.38, a PEG ratio of 2.48 and a beta of 0.67. Qiagen has a fifty-two week low of $39.61 and a fifty-two week high of $57.81.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Amundi boosted its holdings in shares of Qiagen by 4.4% during the third quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after acquiring an additional 181,509 shares during the period. Boston Partners bought a new position in shares of Qiagen during the third quarter worth approximately $179,450,000. Sei Investments Co. lifted its holdings in Qiagen by 5.0% during the 3rd quarter. Sei Investments Co. now owns 1,902,296 shares of the company’s stock worth $84,995,000 after purchasing an additional 90,294 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Qiagen in the 3rd quarter valued at $58,079,000. Finally, Invesco Ltd. boosted its stake in Qiagen by 29.1% in the 3rd quarter. Invesco Ltd. now owns 1,298,776 shares of the company’s stock valued at $58,029,000 after purchasing an additional 292,751 shares during the period. 70.00% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 10th. UBS Group reiterated a “neutral” rating on shares of Qiagen in a research note on Wednesday, January 21st. Barclays set a $58.00 price objective on shares of Qiagen and gave the company an “overweight” rating in a research report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $59.00 target price on shares of Qiagen in a report on Thursday. Three research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $53.90.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.